Literature DB >> 20663363

Revascularization Using an Extracorporeal Pump for the Treatment of Cerebral Embolism in the Acute Stage. For Protection of the Brain Tissue from Irreversible Change due to Cerebral Embolism.

M Sonobe1, Y Nakai, Y Matsumaru, K Sugita.   

Abstract

SUMMARY: Object. For patients with cerebral embolism, we are using an extracorporeal pump to rev ascularize the more peripheral brain tissues far from the thrombus, proceeding the microcatheter beyond the thrombus, and dissolving the thrombus during a satisfactory time as required. Methods. As the critical cerebral blood flow is thought to be below 30 mlllOOglmin, in the case of middle cerebral artery occlusion at the Ml portion, over 15mllmin. of arterial blood is necessary to protect the brain tissue from irreversible change. One thousand and eight hundred mmHg (about 2 atoms) of pump pressure is necessary to send l5mllmin. of blood through the microcatheter (110 cm, FastTrucker 18, Boston). It was confirmed by laboratory and clinical data that hemolysis of the pump action is not sufficient to aggravate kidney function. Conclusion. This method enables the protection of brain tissues from irreversible change after cerebral embolism, and extends the time sufficiently for thrombolysis.

Entities:  

Year:  2002        PMID: 20663363      PMCID: PMC3621044          DOI: 10.1177/159101990100700406

Source DB:  PubMed          Journal:  Interv Neuroradiol        ISSN: 1591-0199            Impact factor:   1.610


  8 in total

1.  Multivariable analysis of predictive factors related to outcome at 6 months after intra-arterial thrombolysis for acute ischemic stroke.

Authors:  T Ueda; S Sakaki; Y Kumon; S Ohta
Journal:  Stroke       Date:  1999-11       Impact factor: 7.914

2.  Regional ischemia and ischemic injury in patients with acute middle cerebral artery stroke as defined by early diffusion-weighted and perfusion-weighted MRI.

Authors:  G Rordorf; W J Koroshetz; W A Copen; S C Cramer; P W Schaefer; R F Budzik; L H Schwamm; F Buonanno; A G Sorensen; G Gonzalez
Journal:  Stroke       Date:  1998-05       Impact factor: 7.914

3.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings.

Authors: 
Journal:  N Engl J Med       Date:  1985-04-04       Impact factor: 91.245

4.  PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism.

Authors:  G J del Zoppo; R T Higashida; A J Furlan; M S Pessin; H A Rowley; M Gent
Journal:  Stroke       Date:  1998-01       Impact factor: 7.914

5.  Utilization of Extracorporeal Pump during Local Intra-arterial Fibrinolysis in the Treatment of Acute Cerebral Arterial Occlusion. A Case Report.

Authors:  Y Matsumaru; M Sonobe; R Mashiko; M Sugimori; S Takahashi; T Nose
Journal:  Interv Neuroradiol       Date:  2001-05-15       Impact factor: 1.610

Review 6.  Acute ischemic stroke therapy. A clinical overview.

Authors:  M Z Onal; M Fisher
Journal:  Eur Neurol       Date:  1997       Impact factor: 1.710

7.  Fibrinolytic therapy for acute embolic stroke: intravenous, intracarotid, and intra-arterial local approaches.

Authors:  O Sasaki; S Takeuchi; T Koike; T Koizumi; R Tanaka
Journal:  Neurosurgery       Date:  1995-02       Impact factor: 4.654

8.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

Authors:  W Hacke; M Kaste; C Fieschi; D Toni; E Lesaffre; R von Kummer; G Boysen; E Bluhmki; G Höxter; M H Mahagne
Journal:  JAMA       Date:  1995-10-04       Impact factor: 56.272

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.